Sales in the US should be accretive to top and bottom lines throughout 2013. The bigger question is how much demand there will be for this test over existing technologies testing for the same pathogen.... It really will be competive based on cost as well as ease of use, rapid test results and accuracy. Now it's up to the marketing folks to make it happen.
Currently approved moeluclar testing cost 18 to 35 dollars per test, and requires expensive capital outlay for purchase of equipment to run the tests which also require a nucleic acid extraction step before running the test. The Quidel amplivue C. diff molecular test requires no capital outlay for equipment purchase and maintenance, eliminates the nucleic acid extraction step, thereby shortening turnover time for test resutls, and is a compact hand held device, allowing ease of use and freeing more space in the lab. It should command a price competitve with existing molecular tests of $35 per test, with an expected savings in both capital equipment costs, and effieicines in techanician time by elimiinating the nucleic extraction step in testing.